Antiviral therapy lowers taurochenodeoxycholic acid concentrations in patients with hepatitis B virus cirrhosis, reflecting changes in bile acid balance with viral suppression.
Accelerated approval granted to Wegovy for treatment of noncirrhotic metabolic dysfunction–associated steatohepatitis in adults with stage F2 to F3 fibrosis.
Stigmatizing language on transplant websites may deter patients with alcohol use disorder and alcohol-associated liver disease from seeking necessary medical care.
Investigators may have uncovered a new factor contributing to the rising incidence of metabolic dysfunction–associated steatotic liver disease among Latinx pediatric patients.